Dova Pharmaceuticals (NASDAQ:DOVA) Sees Strong Trading Volume

Dova Pharmaceuticals Inc (NASDAQ:DOVA) shares saw an uptick in trading volume on Tuesday . 1,057,297 shares were traded during mid-day trading, an increase of 195% from the previous session’s volume of 357,924 shares.The stock last traded at $27.90 and had previously closed at $27.95.

A number of brokerages recently weighed in on DOVA. Oppenheimer began coverage on Dova Pharmaceuticals in a report on Thursday, August 29th. They issued an “outperform” rating and a $30.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on Dova Pharmaceuticals from $13.00 to $15.00 and gave the company an “underweight” rating in a report on Friday, July 12th. Zacks Investment Research cut Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, September 25th. Evercore ISI upgraded Dova Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $15.00 target price on the stock in a report on Monday, July 1st. Finally, BidaskClub upgraded Dova Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $22.93.

The stock has a 50 day simple moving average of $16.36 and a 200 day simple moving average of $12.59. The company has a market cap of $804.96 million, a price-to-earnings ratio of -10.72 and a beta of 2.57. The company has a quick ratio of 5.37, a current ratio of 5.64 and a debt-to-equity ratio of 0.41.

Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.03). The company had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.63 million. Dova Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 544.09%. As a group, equities research analysts expect that Dova Pharmaceuticals Inc will post -2.45 EPS for the current fiscal year.

In related news, Director Paul B. Manning acquired 28,062 shares of Dova Pharmaceuticals stock in a transaction on Friday, August 9th. The shares were bought at an average price of $15.87 per share, for a total transaction of $445,343.94. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Kevin Laliberte sold 3,100 shares of the business’s stock in a transaction dated Wednesday, September 25th. The stock was sold at an average price of $20.00, for a total value of $62,000.00. In the last 90 days, insiders have acquired 183,707 shares of company stock worth $2,985,929 and have sold 12,069 shares worth $199,853. Insiders own 60.30% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the business. Capital Investment Advisory Services LLC lifted its stake in shares of Dova Pharmaceuticals by 222.2% during the second quarter. Capital Investment Advisory Services LLC now owns 2,900 shares of the company’s stock worth $45,000 after purchasing an additional 2,000 shares in the last quarter. Quantamental Technologies LLC increased its position in shares of Dova Pharmaceuticals by 1,100.0% during the second quarter. Quantamental Technologies LLC now owns 2,400 shares of the company’s stock worth $34,000 after acquiring an additional 2,200 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of Dova Pharmaceuticals by 22.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 13,300 shares of the company’s stock worth $336,000 after acquiring an additional 2,400 shares during the last quarter. Doyle Wealth Management purchased a new stake in shares of Dova Pharmaceuticals during the second quarter worth about $49,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Dova Pharmaceuticals by 6.3% during the second quarter. Charles Schwab Investment Management Inc. now owns 67,386 shares of the company’s stock worth $951,000 after acquiring an additional 3,992 shares during the last quarter. Institutional investors own 32.18% of the company’s stock.

About Dova Pharmaceuticals (NASDAQ:DOVA)

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Further Reading: Support Level

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.